Is Estrella Immunopharma going out of business?

ESTRELLA IMMUNOPHARMA, INC. (ESLA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ESTRELLA IMMUNOPHARMA, INC. (ESLA) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $100K of cash and short-term investments against $17.0M of annual burn. Adjusted shares outstanding increased 17.6% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Return on Assets: -715.93%
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 17.65% (YoY)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-08-22.